Autologous Drug-Resistant Gamma-Delta T cells

INB-200 is our genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This product is the first genetically engineered gamma-delta T cell therapy to be administered to patients and is currently in a Phase 1 clinical trial. Our initial indication is newly diagnosed Glioblastoma (GBM).

Since 2005 the standard of care treatment for GBM has been surgical resection followed by radiation and chemotherapy, referred to as the Stupp regimen. Currently, the majority of patients relapse in less than one year with very few patients surviving beyond five years. We engineered INB-200 to be resistant to alkylating chemotherapy such that it can be used as an adjuvant with the current standard-of-care to potentially drive improved anti-tumor response. The Phase 1 repeat dose escalation clinical trial of INB-200 is being conducted in newly diagnosed GBM patients at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.


Allogeneic Gamma-Delta T cells

INB-100 is our allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell immunotherapy.

HSCT procedures have increased over the last 20 years, with over 9,000 patients treated in the United States in 2018. Our scientific founder, Dr. Lawrence Lamb, Ph.D., was the first person in the early 1990’s to describe a survival benefit in HSCT patients with naturally elevated levels of circulating gamma-delta T cells. INB-100 was designed to translate this observation into a treatment and provides donor derived allogeneic gamma-delta T cells to patients following their HSCT. We believe the ability of INB-100 to kill residual cancerous cells, coupled with the correlation between gamma-delta T cells and longer-lasting remissions in allogeneic HSCT patients, may provide a benefit in combination with the standard of care. We are conducting a Phase 1 dose escalation clinical trial of INB-100 in allogeneic HSCT patients at the University of Kansas Cancer Center.


Allogenic Drug-Resistant Gamma-Delta T cells

INB-400 is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” drug resistant gamma-delta T cell therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an IND submission for INB-400. The INB-400 product candidate will be a genetically modified DRI allogeneic candidate with an initial indication in newly diagnosed GBM. IN8bio anticipates also investigating antitumor activity in other solid tumors commonly treated with alkylating agents such as TMZ, darcarbazine and nitrosoureas.


Drug-Resistant CAR Gamma-Delta T cells

INB-300 is a preclinical product candidate with our DRI and CAR gamma-delta T cell combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM and has been previously developed as a tumor paint in this setting. Chlorotoxin has also been observed to bind other solid tumors including lung, breast and prostate cancers, among others. This program is currently in animal models.